Mirikizumab Beats Placebo, Secukinumab for Psoriasis Mirikizumab Beats Placebo, Secukinumab for Psoriasis

52-week trial data pitting an interleukin-23 drug against an IL-17 inhibitor and placebo offers insight on efficacy and safety.Medscape Medical News

Source: Medscape Dermatology Headlines - November 2, 2020 Category: Dermatology Tags: Dermatology News Source Type: news